Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.

BACKGROUND Resting heart rate (HR) is a predictor of adverse outcome in patients with heart failure (HF). Whether changes in HR over time in patients with chronic HF are also associated with adverse outcome is unknown. We explored the relationship between changes in HR from a preceding visit, time-updated HR (i.e. most recent available HR value from a clinic visit) and subsequent outcomes in patients with chronic HF. METHODS AND RESULTS We studied 7599 patients enrolled in the candesartan in heart failure: assessment of reduction in mortality and morbidity program. We calculated change in HR from the preceding visit and explored its association with outcomes in Cox proportional hazards models, as well the association between time-updated HR and outcome. An increase in HR from preceding visit was associated with a higher risk of all-cause mortality and the composite endpoint of cardiovascular death or hospitalization for HF (adjusted hazard ratio 1.06, 95% confidence intervals, CI: 1.05-1.08, P < 0.001, per 5 b.p.m. higher HR), with lowering of HR being associated with lower risk, adjusting for covariates, including time-updated β-blocker dose and baseline HR. Time-updated resting HR at each visit was also associated with risk (adjusted hazard ratio 1.07, 95% CI: 1.06-1.09; P < 0.001, per 5 b.p.m. higher HR). CONCLUSIONS Change in HR over time predicts outcome in patients with chronic HF, as does time-updated HR during follow-up. These data suggest that frequent outpatient monitoring of HR, and identification of changes over time, possibly with remote technologies, may identify patients with HF who may be at increased risk of rehospitalization or death.

[1]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[2]  Javaid Nauman,et al.  Temporal changes in resting heart rate and deaths from ischemic heart disease. , 2011, JAMA.

[3]  J. Connell,et al.  Resting Heart Rate Pattern During Follow-Up and Mortality in Hypertensive Patients , 2010, Hypertension.

[4]  G. Jennings,et al.  Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. , 1994, Journal of the American College of Cardiology.

[5]  Jean-Claude Tardif,et al.  Resting heart rate in cardiovascular disease. , 2007, Journal of the American College of Cardiology.

[6]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[7]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[8]  P. Poole‐Wilson,et al.  Mode of death in heart failure: findings from the ATLAS trial , 2003, Heart.

[9]  Michael Böhm,et al.  Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial , 2010, The Lancet.

[10]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[11]  X. Jouven,et al.  Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. , 2009, The American journal of cardiology.

[12]  G. Davey Smith,et al.  Secular trends in heart rate in young adults, 1949 to 2004: analyses of cross sectional studies , 2005, Heart.

[13]  M. Bernard Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial , 2011 .

[14]  K. Swedberg,et al.  Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. , 2012, Journal of the American College of Cardiology.

[15]  P. Poole‐Wilson,et al.  Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. , 2005, European heart journal.

[16]  P. Armstrong,et al.  Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. , 2009, Annals of internal medicine.

[17]  S. Solomon,et al.  Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. , 2012, Journal of the American College of Cardiology.

[18]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[19]  John G F Cleland,et al.  Is heart rate important for patients with heart failure in atrial fibrillation? , 2014, JACC. Heart failure.

[20]  S. Julius,et al.  Elevated Heart Rate: A Major Risk Factor for Cardiovascular Disease , 2004, Clinical and experimental hypertension.

[21]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.